Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 2/20 | 0.40 |
| ▸ | HTR2B | P41595 | 2/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | TUBB4A | P04350 | 3/20 | 0.38 |
| ▸ | TUBB | P07437 | 3/20 | 0.38 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.38 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.38 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.38 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.38 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.38 |
| ▸ | TUBB2A | Q13885 | 3/20 | 0.38 |
| ▸ | TUBB8 | Q3ZCM7 | 3/20 | 0.38 |
| ▸ | TUBA3E | Q6PEY2 | 3/20 | 0.38 |
| ▸ | TUBA1A | Q71U36 | 3/20 | 0.38 |
| ▸ | TUBA1C | Q9BQE3 | 3/20 | 0.38 |
| ▸ | TUBB6 | Q9BUF5 | 3/20 | 0.38 |
| ▸ | TUBB2B | Q9BVA1 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13908971 | 0.89 | TNKS2 (0.62) | TNKS2HTR2AHTR2CHTR2BAKR1B1 | |
| SCHEMBL5782140 | 0.85 | ALDH1A1 (0.46) | TNKS2HTR2AHTR2CHTR2BAKR1B1 | |
| SCHEMBL920600 | 0.84 | HSD17B10 (0.41) | TNKS2TAAR1TSHRMAPK1POLB | |
| SCHEMBL31528163 | 0.81 | CA1 (0.46) | TNKS2TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL7376461 | 0.80 | HTR2A (0.49) | TNKS2HTR2AHTR2CHTR2BTUBB4A | |
| SCHEMBL1171727 | 0.80 | PTGS2 (0.50) | TNKS2PTGS2 | |
| SCHEMBL13220709 | 0.80 | PTGS2 (0.57) | TNKS2HTR2AHTR2CHTR2BTUBB1 | |
| SCHEMBL13015950 | 0.78 | ERN1 (0.39) | PTPN1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL4035285 | 0.78 | HTR2A (0.46) | TNKS2HTR2AHTR2CHTR2BAKR1B1 | |
| SCHEMBL15240817 | 0.78 | TNKS2 (0.67) | TNKS2HTR2AHTR2CHTR2BAKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130289109-A1 | INHIBITORS OF ALPHA4 MEDIATED CELL ADHESION | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-10-31 | — | — | US | disclosed |
| US-8501809-B2 | Inhibitors of α4 mediated cell adhesion | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-08-06 | — | — | US | disclosed |
| US-20110077299-A1 | INHIBITORS OF ALPHA4 MEDIATED CELL ADHESION | KAWAGUCHI TAKAYUKI | 2011-03-31 | — | — | US | disclosed |
| US-7872151-B2 | asthma, allergic conditions such as rhinitis, inflammatory bowel disease such as ulcerative colitis and Crohn's disease, rheumatoid arthritis, atopic dermatitis, multiple sclerosis; condensing N-(2,6-Difluorobenzoyl)-4-(2,6-dimethoxy-4-formal methylphenyl)-L-phenylalanine ethyl ester with ethanol | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-01-18 | — | — | US | disclosed |
| US-20100113820-A1 | INHIBITORS OF ALPHA4 MEDIATED CELL ADHESION | KAWAGUCHI TAKAYUKI | 2010-05-06 | — | — | US | disclosed |
| US-7671090-B2 | Administering N-(2,6-Dichlorobenzoyl)-4-(2,6-dimethoxy-4-methoxymethylphenyl)-L-phenylalanine ethyl ester for therapy of asthma, inflammatory bowel disease, rheumatoid arthritis and atopic dermatitis | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-03-02 | — | — | US | disclosed |
| US-20090111879-A1 | INHIBITORS OF ALPHA4 MEDIATED CELL ADHESION | KAWAGUCHI TAKAYUKI | 2009-04-30 | — | — | US | disclosed |
| US-7456217-B2 | Inhibitors of alpha4 mediated cell adhesion | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-11-25 | — | — | US | disclosed |
| US-20080076943-A1 | 7-PHENYLPYRAZOLOPYRIDINE COMPOUNDS | HIBI SHIGEKI | 2008-03-27 | — | — | US | disclosed |
| US-20080076943-A1 | 7-PHENYLPYRAZOLOPYRIDINE COMPOUNDS | HIBI SHIGEKI | 2008-03-27 | — | — | US | disclosed |
| EP-1049662-B1 | INHIBITORS OF ALPHA4 MEDIATED CELL ADHESION | TANABE SEIYAKU CO (JP) | 2006-06-21 | — | — | EP | disclosed |
| US-7026501-B2 | Inhibitors of α4 mediated cell adhesion | TANABE SEIYAKU CO., LTD. (JP) | 2006-04-11 | — | — | US | disclosed |
| US-20050282900-A1 | Inhibitors of alpha4 mediated cell adhesion | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2005-12-22 | — | — | US | disclosed |
| EP-1315694-B1 | INHIBITORS OF ALPHA 4 MEDIATED CELL ADHESION | TANABE SEIYAKU CO (JP) | 2005-04-06 | — | — | EP | disclosed |
| US-6855843-B2 | Inhibitors of α4 mediated cell adhesion | TANABE SEIYAKU CO., LTD. (JP) | 2005-02-15 | — | — | US | disclosed |
| US-20030191118-A1 | Inhibitors of alpha4 mediated cell adhesion | TANABE SEIYAKU CO., LTD. | 2003-10-09 | — | — | US | disclosed |
| US-20030176498-A1 | Inhibitors of alpha4mediated cell adhesion | TANABE SEIYAKU CO., LTD. (JP) | 2003-09-18 | — | — | US | disclosed |
| EP-1315694-A2 | INHIBITORS OF ALPHA 4 MEDIATED CELL ADHESION | Tanabe Seiyaku Co., Ltd. (JP) | 2003-06-04 | — | — | EP | disclosed |
| US-6521666-B1 | Inhibitors of α4 mediated cell adhesion | TANABE SEIYAKU CO., LTD. (JP) | 2003-02-18 | — | — | US | disclosed |
| WO-2002018320-A2 | INHIBITORS OF α4 MEDIATED CELL ADHESION | TANABE SEIYAKU CO., LTD. (JP) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282900-A1 | Inhibitors of alpha4 mediated cell adhesion | ITGB4, ITGA4, VCAM1 | TNKS2 4426/4885HTR2A 3137/4885HTR2C 2631/4885 |
| US-20080076943-A1 | 7-PHENYLPYRAZOLOPYRIDINE COMPOUNDS | MC2R, CRHR1, CRHR2 | TNKS2 2953/4885HTR2A 113/4885HTR2C 72/4885 |
| US-20130289109-A1 | INHIBITORS OF ALPHA4 MEDIATED CELL ADHESION | ITGB4, ITGA4, VCAM1 | TNKS2 4426/4885HTR2A 3137/4885HTR2C 2631/4885 |
| US-20110077299-A1 | INHIBITORS OF ALPHA4 MEDIATED CELL ADHESION | ITGB4, ITGA4, VCAM1 | TNKS2 4426/4885HTR2A 3137/4885HTR2C 2631/4885 |
| US-20100113820-A1 | INHIBITORS OF ALPHA4 MEDIATED CELL ADHESION | ITGB4, ITGA4, VCAM1 | TNKS2 4426/4885HTR2A 3137/4885HTR2C 2631/4885 |
| US-20030191118-A1 | Inhibitors of alpha4 mediated cell adhesion | ITGB4, ITGA4, VCAM1 | TNKS2 4390/4885HTR2A 2799/4885HTR2C 2342/4885 |
| US-20030176498-A1 | Inhibitors of alpha4mediated cell adhesion | ITGB4, VCAM1, EPCAM | TNKS2 4151/4885HTR2A 2898/4885HTR2C 2974/4885 |
| US-20090111879-A1 | INHIBITORS OF ALPHA4 MEDIATED CELL ADHESION | ITGB4, ITGA4, VCAM1 | TNKS2 4426/4885HTR2A 3137/4885HTR2C 2631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.